We’re #hiring. Know anyone who might be interested? Please feel free to share this information with others who may be interested.

We’re #hiring. Know anyone who might be interested? Please feel free to share this information with others who may be interested.

Johnson & Johnson reported worldwide sales of $320 million for RYBREVANT® and LAZCLUZE® (lazertinib) in Q3 2026, representing 62.3% year-on-year growth. The combined products generated
Yuhan Corporation presented population PK/PD modeling results for YH35995 at the American Conference on Pharmacometrics (ACoP 2026) on October 12, 2026. YH35995 is a novel